Felbamate (FBM) is a new antiepileptic drug that has been evaluated in the Lennox-Gastaut Syndrome (LGS). When tested against placebo in an add-on, randomized, double-blind trial, FBM reduced the total seizure frequency of >50% in at least 50% of subjects. FBM appears to be well tolerated. A subsequent open-label follow-up study demonstrated that the improvement has persisted for up to 12 months. Uncontrolled studies indicate that FBM could be effective also in other pediatric epileptic syndromes.
|Translated title of the contribution||Clinical experience with Felbamate in paediatric age|
|Number of pages||4|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - 1994|
ASJC Scopus subject areas
- Clinical Neurology